Aldeyra Therapeutics, Inc. financial data

Symbol
ALDX on Nasdaq
Location
131 Hartwell Avenue, Suite 320, Lexington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 395 % -34.1%
Debt-to-equity 50.8 % +81.8%
Return On Equity -33.8 %
Return On Assets -47.9 % -42.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.2M shares +1.03%
Common Stock, Shares, Outstanding 60.2M shares +1.03%
Entity Public Float 192M USD -60.3%
Common Stock, Value, Issued 60.2K USD +1.03%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +1%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 36M USD -5.02%
General and Administrative Expense 9.19M USD -21.8%
Operating Income (Loss) -45.2M USD +8.99%
Nonoperating Income (Expense) 1.98M USD -59.1%
Net Income (Loss) Attributable to Parent -43.2M USD +3.58%
Earnings Per Share, Basic 0 USD/shares +2.67%
Earnings Per Share, Diluted 0 USD/shares +2.67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.3M USD -12.9%
Marketable Securities, Current 16M USD -64.2%
Other Assets, Current 756K USD
Assets, Current 77.5M USD -33.6%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 341K USD +3.34%
Assets 77.8M USD -33.7%
Accounts Payable, Current 13.4K USD -92.8%
Employee-related Liabilities, Current 4.48M USD +4.69%
Accrued Liabilities, Current 7M USD -32.8%
Liabilities, Current 28.5M USD +66.1%
Operating Lease, Liability, Noncurrent 72.5K USD +3.28%
Liabilities 28.6M USD -11.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 815 USD -98.8%
Retained Earnings (Accumulated Deficit) -477M USD -9.95%
Stockholders' Equity Attributable to Parent 49.2M USD -42.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 123M USD
Liabilities and Equity 77.8M USD -33.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.5M USD -25%
Net Cash Provided by (Used in) Financing Activities 1M USD +5413%
Net Cash Provided by (Used in) Investing Activities 7.29M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 60.2M shares +1.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.18M USD +89.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.3M USD -12.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 416K USD -5.36%
Deferred Tax Assets, Valuation Allowance 121M USD +15.9%
Deferred Tax Assets, Gross 122M USD +15.8%
Operating Lease, Liability 344K USD +3.3%
Depreciation 60.9K USD +0.46%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -43.3M USD +3.29%
Lessee, Operating Lease, Liability, to be Paid 366K USD +3.3%
Operating Lease, Liability, Current 272K USD +3.31%
Lessee, Operating Lease, Liability, to be Paid, Year Two 295K USD +3.28%
Lessee, Operating Lease, Liability, to be Paid, Year One 71.3K USD +3.39%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.4K USD +3.29%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 80.8K USD -42.1%
Share-based Payment Arrangement, Expense 6.26M USD +6%
Interest Expense 2.03M USD +7.01%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%